Evaluation of an individualized starting-dose of niraparib in the PRIMA/ENGOT-OV26/GOG-3012 study

• Published in: Journal of clinical oncology Vol. 38; no. 15_suppl; p. 6050
• Main Authors: Mirza, Mansoor Raza, Gonzalez Martin, Antonio, Graybill, Whitney, O'Malley, David M., Gaba, Lydia, Yap, Oi Wah S., Guerra, Eva M., Rose, Peter Graham, Baurain, Jean-Francois, Ghamande, Sharad A., denys, Hannelore, Prendergast, Emily, Pisano, Carmela, Follana, Philippe, Baumann, Klaus, Calvert, Paula, Korach, Jacob, Li, Yong, Gupta, Divya, Monk, Bradley J.
• Format: Journal Article
• Language: English
• Published: 20.05.2020

Abstract only 6050 Background: Niraparib is approved at a fixed starting dose (FSD) of 300 mg QD for maintenance treatment of patients (pts) with recurrent ovarian cancer (OC) achieving a complete or partial response to platinum-based chemotherapy based in the ENGOT-OV16/NOVA study. A post-hoc analy...